Anika Therapeutics (ANIK) Tops Q1 EPS by 27c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.58 +0.68%
EPS Growth %: +950.0%
Financial Fact:
Product revenue: 25.78M
Today's EPS Names:
OMID, BCML, CZNC, More
EPS Growth %: +950.0%
Financial Fact:
Product revenue: 25.78M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.09, $0.27 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $40.5 million versus the consensus estimate of $41.55 million.
GUIDANCE:
Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.3 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- OFG Bancorp (OFG) Tops Q3 EPS by 10c
- Abbott (ABT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
